Skip to search formSkip to main contentSkip to account menu

CC-122

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier.
Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) are limited with no standard of care… 
2019
2019
Genome-wide CRISPR Screens Reveal Genetic Mediators of Cereblon Modulator Toxicity in Primary Effusion Lymphoma
Genome-wide CRISPR/Cas9 screens represent a powerful approach to study mechanisms of drug action and resistance. Cereblon… 
2019
2019
Single‐Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC‐122) in Subjects With Mild, Moderate, or Severe Renal Impairment
CC‐122 (Avadomide) is a nonphthalimide analogue of thalidomide that has multiple pharmacological activities including immune… 
2019
2019
Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects
Avadomide (CC‐122) is a novel immunomodulatory drug that binds to cereblon, a member of the Cullin 4‐RING E3 ubiquitin ligase… 
2018
2018
Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma
Introduction:The prognosis is poor for patients with follicular lymphoma (FL) who experience early relapse within 2 years of… 
2015
2015
CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Background: CC-122, a first in class PPM™ pleiotropic pathway modifier, has anti-tumor activity against B cell lymphomas. The… 
2014
2014
CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma…
Background: CC-122 is a novel non-phthalimide analog of the IMiDs ® immunomodulatory drugs (lenalidomide and pomalidomide) and a… 
2014
2014
CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways
Background : IMiDs® Immunomodulatory agent lenalidomide (Len) is active in a range of hematologic cancers including diffuse large… 
2013
2013
A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin…
![Graphic][1] Background CC-122 is a novel PPMTM compound with multiple biological activities, including potent anti… 
2012
2012
CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.
Abstract 2963 Background: The immunomodulatory agents thalidomide (THAL), lenalidomide (LEN), and pomalidomide (POM) have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)